Cell therapy technology provider Pluristyx and biotechnology company Humacyte have entered an agreement to develop advanced cellular treatments for type 1 diabetes.
According to the agreement, Humacyte has been granted rights to use Pluristyx’s PluriBank cell lines in its BioVascular Pancreas development program. The program aims to combine Humacyte’s Acellular Tissue Engineered Vessel (ATEV) with insulin-producing cells derived from Pluristyx’s best-in-class iPSC lines to create a potential cure for insulin-dependent diabetes and for the treatment of type 1 diabetes.
Pluristyx is a biotechnology company that advances cellular therapies through innovative tools and technologies. The company specializes in providing induced pluripotent stem cells (iPSCs) and related expertise to accelerate the development and commercialization of cellular therapeutics. It offers a range of products and services, including the proprietary PluriFreeze cryopreservation media, clinical-grade iPSCs, and the panCELLa platform, which includes technologies such as the FailSafe safety switch and iACT Stealth Cells for immune evasion, to increase the efficiency of the development process.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.